Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kaitong Buzhure is a traditional Uyghur medicine (TUM) developed by the Xinjiang Uygur Autonomous Region Institute of Drug Research. It is primarily indicated for the treatment of hepatitis A and other forms of acute jaundice hepatitis. Formulated based on the principles of Uyghur medicine, it is designed to treat "Buzhure" (heat-related) syndromes by clearing heat, detoxifying the liver, and acting as a cholagogue to promote bile flow. The medication is typically administered in granule or tablet form and is recognized for its ability to reduce jaundice and normalize liver enzyme levels such as ALT and AST. It is officially included in the Chinese pharmaceutical standards for Uyghur medicines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kaitong Buzhure.